Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wetmore JB et al. - The balance of evidence now supports a treatment paradigm in which calcimimetics are the most appropriate primary treatment for SHPT in the majority of end stage renal disease patients, but which nevertheless acknowledges an important role for modest doses of activated vitamin D sterols.

Related Articles

Predictors of Early Postoperative Hypocalcemia in Hemodialysis Patients With Secondary Hyperparathyroidism
Transplantation Proceedings, 11/20/09    Relevance Score: 87%

Postexercise Cardiac Performance Among Patients With Mild Primary Hyperparathyroidism
The Endocrinologist, 11/16/09    Relevance Score: 87%

Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism
Diabetic Medicine, 10/02/09    Relevance Score: 87%

Multimodality imaging in hyperparathyroidism
Postgraduate Medical Journal, 11/10/09    Relevance Score: 85%

No recurrence of sporadic primary hyperparathyroidism when cure is established 6 months after parathyroidectomy
European Journal of Endocrinology, 11/05/09    Relevance Score: 85%

Today in Endocrinology...keeping you current

The renal vascular response to diabetes
Current Opinion in Nephrology and Hypertension, 12/15/09

The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with Chronic Kidney Disease: a randomised controlled trial
BMC Nephrology, 12/11/09

FGF23–parathyroid interaction: implications in chronic kidney disease
Kidney International, 12/11/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address